Related Experiment Video
Updated: May 31, 2026
09:06
Induction of Petite Colonies in Candida glabrate via Rose Bengal-Mediated Photodynamic Therapy
Published on: March 29, 2024
Posaconazole: a new antifungal weapon
Georgios Aperis1, Polichronis Alivanis
1Department of Nephrology, General Hospital of Rhodes, Greece. gaperis@yahoo.com
Reviews on Recent Clinical Trials
|June 21, 2011
Summary
Posaconazole offers broad-spectrum antifungal activity, effectively treating resistant invasive fungal infections (IFI). Clinical trials show its efficacy in salvage therapy and prophylaxis for immunocompromised patients, with favorable pharmacokinetics and safety.
Area of Science:
- Mycology
- Infectious Diseases
- Pharmacology
Background:
- Invasive fungal infections (IFI) have increased due to longer survival in high-risk patients.
- Traditional antifungals like Amphotericin B, fluconazole, and itraconazole face issues with toxicity and emerging resistance.
- Newer agents like voriconazole and echinocandins have limitations against specific pathogens.
Purpose of the Study:
- To evaluate the efficacy and safety of posaconazole, a broad-spectrum triazole antifungal.
- To assess posaconazole's role in salvage treatment and prophylaxis of IFI in immunocompromised populations.
Main Methods:
- Review of clinical trial data for posaconazole in treating and preventing IFI.
- Analysis of posaconazole's activity against various fungal pathogens, including resistant strains.
- Evaluation of posaconazole's pharmacokinetic profile and side effect profile.
Main Results:
- Posaconazole demonstrates broad-spectrum activity against Candida, Aspergillus, Cryptococcus, Zygomycetes, and other fungi.
- It is effective against fungal strains resistant to older antifungals.
- Clinical trials support its use in salvage therapy and prophylaxis for neutropenic patients and post-hematopoietic stem cell transplantation patients.
Conclusions:
- Posaconazole represents a significant advancement in managing invasive fungal infections.
- Its broad spectrum and activity against resistant pathogens offer a valuable therapeutic option.
- Favorable pharmacokinetics and a low side effect profile enhance its utility in critically ill patients.
Related Concept Videos
01:15Antifungal Agents
Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
01:20Candidiasis
Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
01:28Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
01:27Cryptococcal Meningitis
Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...